The preclinical potential of alectinib in ALK-positive NB has further been investigated by Alam et al. who evaluated the compound’s ability to abrogate the activity of different full-length ALK gain-of-function mutations found in certain NB cases. The gene discussed is ALK; the disease is neuroblastoma.